The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)

K He, B Cui, G Li, H Wang, K Jin… - OncoTargets and therapy, 2012 - Taylor & Francis
Significant progression has been achieved in the treatment of metastatic colorectal cancer
(mCRC) in recent years. This has been partly attributed to successfully incorporating new …
被引用次数：38 相关文章
[PDF] psu.edu

[PDF][PDF] The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)

K He - OncoTargets and Therapy, 2012 - Citeseer
Significant progression has been achieved in the treatment of metastatic colorectal cancer
(mCRC) in recent years. This has been partly attributed to successfully incorporating new …
[HTML] nih.gov

[HTML][HTML] The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)

K He, B Cui, G Li, H Wang, K Jin… - OncoTargets and therapy, 2012 - ncbi.nlm.nih.gov
Significant progression has been achieved in the treatment of metastatic colorectal cancer
(mCRC) in recent years. This has been partly attributed to successfully incorporating new …
[PDF] researchgate.net

[PDF][PDF] The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)

K He - OncoTargets and Therapy, 2012 - researchgate.net
Significant progression has been achieved in the treatment of metastatic colorectal cancer
(mCRC) in recent years. This has been partly attributed to successfully incorporating new …

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC).

K He, B Cui, G Li, H Wang, K Jin, L Teng - Oncotargets and Therapy, 2012 - europepmc.org
Significant progression has been achieved in the treatment of metastatic colorectal cancer
(mCRC) in recent years. This has been partly attributed to successfully incorporating new …

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)

K He, B Cui, G Li, H Wang, K Jin… - OncoTargets and Therapy, 2012 - dovepress.com
Significant progression has been achieved in the treatment of metastatic colorectal cancer
(mCRC) in recent years. This has been partly attributed to successfully incorporating new …
[PDF] semanticscholar.org

[PDF][PDF] The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)

K He - OncoTargets and Therapy, 2012 - pdfs.semanticscholar.org
Significant progression has been achieved in the treatment of metastatic colorectal cancer
(mCRC) in recent years. This has been partly attributed to successfully incorporating new …

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)

K He, B Cui, G Li, H Wang, K Jin, L Teng - OncoTargets and Therapy, 2012 - go.gale.com
Significant progression has been achieved in the treatment of metastatic colorectal cancer
(mCRC) in recent years. This has been partly attributed to successfully incorporating new …

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)

K He, B Cui, G Li, H Wang, K Jin… - OncoTargets and …, 2012 - pubmed.ncbi.nlm.nih.gov
Significant progression has been achieved in the treatment of metastatic colorectal cancer
(mCRC) in recent years. This has been partly attributed to successfully incorporating new …

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)

K He, B Cui, G Li, H Wang, K Jin… - OncoTargets and …, 2012 - search.proquest.com
Significant progression has been achieved in the treatment of metastatic colorectal cancer
(mCRC) in recent years. This has been partly attributed to successfully incorporating new …